# A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer

> **NCT04474470** · PHASE1,PHASE2 · COMPLETED · sponsor: **TyrNovo Ltd.** · enrollment: 52 (actual)

## Conditions studied

- Solid Tumor, Adult
- Squamous Cell Carcinoma of Head and Neck
- Colorectal Adenocarcinoma
- Metastatic Solid Tumor
- Recurrent Solid Tumor
- Head and Neck Cancer

## Interventions

- **DRUG:** NT219
- **DRUG:** NT219 and ERBITUX® - Dose Escalation
- **DRUG:** NT219 and ERBITUX® - Expansion

## Key facts

- **NCT ID:** NCT04474470
- **Lead sponsor:** TyrNovo Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-03
- **Primary completion:** 2024-05-08
- **Final completion:** 2024-05-08
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04474470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04474470, "A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04474470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*